Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB1 | P15086 | 1/20 | 0.70 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.70 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.64 |
| ▸ | ANPEP | P15144 | 1/20 | 0.60 |
| ▸ | ECE1 | P42892 | 1/20 | 0.57 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.57 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.57 |
| ▸ | MMP2 | P08253 | 1/20 | 0.56 |
| ▸ | MMP9 | P14780 | 1/20 | 0.56 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.55 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.55 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.55 |
| ▸ | DPP4 | P27487 | 1/20 | 0.53 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30591026 | 0.95 | CPB1 (0.68) | CPB1CPB2FOLH1ANPEPECE1 | |
| SCHEMBL9846794 | 0.92 | CPB1 (0.67) | CPB1CPB2FOLH1ANPEPECE1 | |
| SCHEMBL8179347 | 0.91 | CPB1 (0.74) | CPB1CPB2FOLH1ECE1MMP2 | |
| SCHEMBL7429424 | 0.90 | FOLH1 (0.77) | CPB1CPB2FOLH1ANPEPDPP8 | |
| SCHEMBL9498688 | 0.89 | FOLH1 (0.67) | CPB1CPB2FOLH1ANPEPDPP8 | |
| SCHEMBL30727540 | 0.88 | CPB1 (0.59) | CPB1CPB2FOLH1ANPEPDPP8 | |
| SCHEMBL24130289 | 0.87 | CPB1 (0.66) | CPB1CPB2FOLH1ANPEPDPP8 | |
| SCHEMBL24130284 | 0.87 | CPB1 (0.66) | CPB1CPB2FOLH1ANPEPDPP8 | |
| SCHEMBL11202618 | 0.85 | FOLH1 (0.67) | CPB1CPB2FOLH1MMP2MMP9 | |
| SCHEMBL1025892 | 0.85 | ANPEP (0.59) | CPB1CPB2FOLH1ANPEPDPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964601-B2 | Agonist or antgonist and binders and inversion of agonist | PALATIN TECHNOLOGIES, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7897721-B2 | Cyclic peptide compositions for treatment of sexual dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-7795378-B2 | Peptide compositions for treatment of sexual dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7732451-B2 | Naphthalene-containing melanocortin receptor-specific small molecule | PALATIN TECHNOLOGIES, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-20100121027-A1 | Cyclic Peptide Compositions for Treatment of Sexual Dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-7709484-B1 | Substituted melanocortin receptor-specific piperazine compounds | PALATIN TECHNOLOGIES, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-7601753-B2 | Pyrrolidine melanocortin-specific compounds | PALATIN TECHNOLOGIES, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20090253713-A1 | Small Molecule Compositions for Sexual Dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2009-10-08 | — | — | US | disclosed |
| US-20090076029-A1 | Compounds and Methods for Treating Obesity | PALATIN TECHNOLOGIES, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-20080234289-A1 | Melanocortin Receptor-Specific Compounds | PALATIN TECHNOLOGIES, INC. (US) | 2008-09-25 | — | — | US | disclosed |
| US-7396814-B2 | Metallopeptide compositions for treatment of sexual dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2008-07-08 | — | — | US | disclosed |
| US-7354923-B2 | Piperazine melanocortin-specific compounds | PALATIN TECHNOLOGIES, INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-20070155670-A1 | Pyrrolidine Melanocortin-Specific Compounds | PALATIN TECHNOLOGIES, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-7189755-B2 | Pyrrolidine melanocortin-specific compounds | PALATIN TECHNOLOGIES, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-20050164914-A1 | Metallopeptide compositions for treatment of sexual dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2005-07-28 | — | — | US | disclosed |
| US-20050130988-A1 | Naphthalene-containing melanocortin receptor-specific small molecule | PALATIN TECHNOLOGIES, INC. (US) | 2005-06-16 | — | — | US | disclosed |
| US-20050124553-A1 | Peptide compositions for treatment of sexual dysfunction | PALATINE TECHNOLOGIES, INC. (US) | 2005-06-09 | — | — | US | disclosed |
| US-20040167201-A1 | Pyrrolidine melanocortin-specific compounds | PALATIN TECHNOLOGIES, INC. (US) | 2004-08-26 | — | — | US | disclosed |
| US-20040157264-A1 | Piperazine melanocortin-specific compounds | PALATIN TECHNOLOGIES, INC. (US) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130988-A1 | Naphthalene-containing melanocortin receptor-specific small molecule | MC1R, MC3R, MC2R | CPB1 4701/4885CPB2 4721/4885FOLH1 2552/4885 |
| US-20040167201-A1 | Pyrrolidine melanocortin-specific compounds | MC3R, MC1R, MC5R | CPB1 2634/4885CPB2 3083/4885FOLH1 1107/4885 |
| US-20040157264-A1 | Piperazine melanocortin-specific compounds | MC1R, MC5R, MC3R | CPB1 4029/4885CPB2 3806/4885FOLH1 1673/4885 |
| US-20090076029-A1 | Compounds and Methods for Treating Obesity | MC4R, MC3R, MC1R | CPB1 1400/4885CPB2 2083/4885FOLH1 1067/4885 |
| US-20070155670-A1 | Pyrrolidine Melanocortin-Specific Compounds | MC3R, MC1R, MC5R | CPB1 2699/4885CPB2 2712/4885FOLH1 1369/4885 |
| US-20090253713-A1 | Small Molecule Compositions for Sexual Dysfunction | PDE3B, PDE3A, PDE5A | CPB1 3873/4885CPB2 3761/4885FOLH1 1674/4885 |
| US-20080234289-A1 | Melanocortin Receptor-Specific Compounds | MC1R, MC3R, MC5R | CPB1 3434/4885CPB2 3905/4885FOLH1 3700/4885 |
| US-20050124553-A1 | Peptide compositions for treatment of sexual dysfunction | RXFP1, EDNRB, EDNRA | CPB1 1278/4885CPB2 1590/4885FOLH1 355/4885 |
| US-20100121027-A1 | Cyclic Peptide Compositions for Treatment of Sexual Dysfunction | VIP, GNRHR, NPR1 | CPB1 1092/4885CPB2 1929/4885FOLH1 350/4885 |
| US-20050164914-A1 | Metallopeptide compositions for treatment of sexual dysfunction | MC1R, SHBG, MTPN | CPB1 899/4885CPB2 1047/4885FOLH1 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.